This means that lowering LDL in plasma results in reduced levels of PAF-AH, and therefore, a longer half-life for PAF [73], that could increase the risk for severe anaphylaxis or, perhaps, other allergic reactions. The gene discussed is PCLAF; the disease is anaphylaxis.